Clinical trial · Observational
A Study of Empirical Antifungal Therapy With Itraconazole
Retrospective Observation of Empirical Antifungal Therapy With Itraconazole
NCT01706562CI-TRIAL-00009518completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the overall success rate of itraconazole intravenous treatment for a period of more than 7 days.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Itraconazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Itraconazole
- interventionNames
- Drug: Itraconazole
Primary outcomes (1)
- measure
- Success rate of itraconazole treatment when used for more than 7 days
- timeFrame
- From 7 days to approximately 2 weeks
- description
- Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
Secondary outcomes (2)
- measure
- Success rate of itraconazole treatment until neutropenia is resolved
- timeFrame
- Approximately 2 weeks
- description
- Treatment success is achieved when neutropenia is resolved, ie, when the blood cells count is within the normal reference range.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with neutropenic fever who receive therapy for inhibiting or preventing development of neoplasms (abnormal growth of tissue) or stem cell transplantation (stem cell is a cell whose daughter cells may differentiate into other cell types) for hematologic malignancies (cancers that affect blood, bone marrow and lymph nodes) * Patients who receive itraconazole intravenous (IV) treatment for more than 7 days Exclusion Criteria: * Childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception * Fever due to documented fungal infection * Hepatic dysfunction * Kidney abnormalities * Patients who are not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug at the investigator's discretion
References
Publications (0)
Data not yet available
No reference posted for this study.